Summary
I am based at the Cancer Research UK Imperial Centre: Clinical Trials Section. I have over 15 years' experience working in cancer trials. Since September 2019 I have been overseeing studies including ovary, breast, cancer of unknown primary, and cervical pre-cancer as well as working on pre- and post-funded studies approved by our trials oversight committee. Our team forms part of the Imperial Clinical Trials Unit (ICTU).
Selected Publications
Journal Articles
Fiorentino F, Krell J, de la Rosa CN, et al., 2022, DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228, Trials, Vol:23, ISSN:1745-6215, Pages:1-15
de la Rosa CN, Krell J, Day E, et al., 2022, Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE), Trials, Vol:23, ISSN:1745-6215, Pages:1-8
Ingemarsdotter CK, Tookman LA, Browne A, et al., 2015, Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control, Molecular Oncology, Vol:9, ISSN:1574-7891, Pages:791-805
McNeish IA, Ledermann JA, Webber L, et al., 2014, A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, Annals of Oncology, Vol:25, ISSN:0923-7534, Pages:1988-1995